Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

MLA

Uemura, Hirotsugu, et al. “Three-Year Follow-up of a Phase II Study of Radium-223 Dichloride in Japanese Patients with Symptomatic Castration-Resistant Prostate Cancer and Bone Metastases.” International Journal of Clinical Oncology, vol. 24, no. 5, May 2019, pp. 557–66. EBSCOhost, https://doi.org/10.1007/s10147-018-01389-4.

APA

Uemura, H., Uemura, H., Nagamori, S., Wakumoto, Y., Kimura, G., Kikukawa, H., Yokomizo, A., Mizokami, A., Kosaka, T., Masumori, N., Kawasaki, Y., Yonese, J., Nasu, Y., Fukasawa, S., Sugiyama, T., Kinuya, S., Hosono, M., Yamaguchi, I., Akagawa, T., & Matsubara, N. (2019). Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology, 24(5), 557–566. https://doi.org/10.1007/s10147-018-01389-4

Chicago

Uemura, Hirotsugu, Hiroji Uemura, Satsohi Nagamori, Yoshiaki Wakumoto, Go Kimura, Hiroaki Kikukawa, Akira Yokomizo, et al. 2019. “Three-Year Follow-up of a Phase II Study of Radium-223 Dichloride in Japanese Patients with Symptomatic Castration-Resistant Prostate Cancer and Bone Metastases.” International Journal of Clinical Oncology 24 (5): 557–66. doi:10.1007/s10147-018-01389-4.